DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026)
DBV Technologies (DBVT) posted Liabilities and Shareholders Equity of $223.2 million for Q2 2026, down 16.22% sequentially from $266.4 million in Q1 2026, and up 55.62% YoY from $143.4 million in Q2 2025.
DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
DBV Technologies has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $223.2 million in Q2 2026.
- Quarterly Liabilities and Shareholders Equity rose 55.62% year-over-year to $223.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $833.8 million (up 136.4% YoY) and the FY2025 annual result came in at $233.7 million, up 255.94% from the prior year.
- Liabilities and Shareholders Equity eased to $223.2 million in Q2 2026 per DBVT's latest filing, from $266.4 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $285.0 million in Q2 2022 and troughed at $50.6 million in Q1 2025.
- A 5-year average of $175.9 million and a median of $186.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 65.34% in 2025, then jumped 426.88% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $246.5 million in 2022, then decreased by 25.77% to $183.0 million in 2023, then tumbled by 64.12% to $65.7 million in 2024, then soared by 255.94% to $233.7 million in 2025, then retreated by 4.49% to $223.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $223.2 million, $266.4 million, and $233.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 223.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 223.20 Mn |
| Mar 31, 2026 | 266.40 Mn |
| Dec 31, 2025 | 233.70 Mn |
| Sep 30, 2025 | 110.50 Mn |
| Jun 30, 2025 | 143.43 Mn |
| Mar 31, 2025 | 50.56 Mn |
| Dec 31, 2024 | 65.66 Mn |
| Sep 30, 2024 | 93.06 Mn |
| Jun 30, 2024 | 114.19 Mn |
| Mar 31, 2024 | 145.90 Mn |
| Dec 31, 2023 | 182.99 Mn |
| Sep 30, 2023 | 189.78 Mn |
| Jun 30, 2023 | 217.52 Mn |
| Mar 31, 2023 | 232.93 Mn |
| Dec 31, 2022 | 246.52 Mn |
| Sep 30, 2022 | 248.12 Mn |
| Jun 30, 2022 | 284.98 Mn |
| Mar 31, 2022 | 117.58 Mn |
| Dec 31, 2021 | 146.72 Mn |
| Sep 30, 2021 | 170.92 Mn |